^
    Back
    Association details:
    Biomarker:KMT2D mutation
    Cancer:Lung Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) +
    SHP099 (PTPN11 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition

    Published date:
    12/15/2022
    Excerpt:
    Combining SHP2 inhibitor SHP099 and pan-ERBB inhibitor afatinib inhibits lung tumor growth in Kmt2d-deficient LUSC murine models and in patient-derived xenografts (PDXs) harboring KMT2D mutations.
    DOI:
    https://doi.org/10.1016/j.ccell.2022.11.015